Eos Energy stock falls after Fuzzy Panda issues short report
Natera, Inc. (NASDAQ:NTRA), a $26.56 billion market cap company, saw Chief Financial Officer Brophy Michael Burkes sell a total of 2,170 shares of common stock between October 22 and October 24, 2025. The sales, totaling $412,951, were executed in a price range of $186.68 to $196.77, with the stock trading near its 52-week high. According to InvestingPro analysis, the company currently appears overvalued relative to its Fair Value.
On October 22, Burkes sold 920 shares at $186.68 per share. On October 23, he sold 495 shares at $187.16 per share to satisfy tax obligations related to vesting Restricted Stock Units. Then, on October 24, Burkes sold 755 shares at $196.77 per share. These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 14, 2024. The timing is notable as Natera has demonstrated strong momentum, with a 54.41% return over the past year. InvestingPro data shows the company maintains a GREAT financial health score, with liquid assets exceeding short-term obligations by 3.72x.
On October 22, Burkes also exercised options to acquire 1,250 shares of Natera’s common stock, with a value of $0. These Restricted Stock Units vest over four years, with 25% vesting on October 22, 2022, and the remaining shares vesting in 12 equal quarterly installments thereafter.
Following these transactions, Burkes directly owns 69,189 shares of Natera, Inc.
In other recent news, Natera has announced several significant developments. The company has reported positive results from its IMvigor011 clinical trial in muscle-invasive bladder cancer (MIBC), which demonstrated the effectiveness of its Signatera test in guiding treatment with adjuvant atezolizumab. Following these findings, BTIG raised its price target for Natera to $210, maintaining a Buy rating, while Canaccord Genuity reiterated its $200 price target, also with a Buy rating. Additionally, Natera has enrolled over 1,600 patients in its EXPAND trial, which evaluates the Fetal Focus single gene noninvasive prenatal test for inherited conditions. This prospective, blinded, multi-site study aims to confirm test results through prenatal or postnatal diagnostic testing. Furthermore, Natera’s Signatera test has shown significant performance in a study of circulating tumor DNA (ctDNA) in testicular cancer patients, outperforming standard tumor markers in predicting patient outcomes. The study, which involved 324 plasma samples from 74 patients, was published in the Journal of Clinical Oncology - Precision Oncology. Natera is also preparing to present 14 abstracts at the European Society for Medical Oncology Congress to reinforce its position in molecular residual disease testing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.